Clover Health Investments, Corp. — Form 8-K Summary
Business context and reporting period
The filing reports a corporate governance change effective April 13, 2021. Clover Health Investments, Corp. is a Delaware corporation whose Class A common stock and redeemable warrants trade on Nasdaq under the symbols CLOV and CLOVW.
Material change
- The Board appointed Demetrios L. Kouzoukas, former Director of the Center for Medicare and Principal Deputy Administrator of the Centers for Medicare & Medicaid Services, as a Class II director and member of the Audit Committee.
- The Board increased its size from six to seven directors.
- Effective April 13, 2021, Mr. Kouzoukas joined the Audit Committee. The filing also lists the updated membership of the Nominating and Corporate Governance Committee and Talent and Compensation Committee.
Financial metrics, liquidity, and compensation
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
- Mr. Kouzoukas will receive a pro rata portion of the $60,000 annual non-employee director cash retainer.
- He will receive a restricted stock unit award under the 2020 Equity Incentive Plan covering Class A common stock with an RSU value of $200,000, subject to the Company’s Director Compensation Policy.
- He entered into the Company’s standard director indemnification agreement, including indemnification and advancement of expenses provisions.
Management commentary, risks, and unusual items
The filing contains no management outlook or operating commentary. It states that there were no arrangements or understandings with other persons regarding Mr. Kouzoukas’s selection, no family relationships with the Company’s directors or executive officers, and no reportable material interest under Item 404(a) of Regulation S-K.
The appointment of a former senior Medicare and CMS official may be relevant to the Company’s healthcare regulatory expertise and governance oversight, but the filing does not state any expected business or financial impact.
Investor verification checklist
- Verify the final seven-member Board composition and committee memberships following the appointment.
- Review the applicable Director Compensation Policy and the terms, vesting conditions, and accounting treatment of the $200,000 RSU award.
- Review the referenced standard indemnification agreement filed as Exhibit 10.2 to the January 12, 2021 Form 8-K.
- Assess any subsequent filings for changes to Mr. Kouzoukas’s role, committee assignments, compensation, or related-party disclosures.